Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton Sells 18,333 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYSGet Free Report) CEO Jon Congleton sold 18,333 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.06, for a total value of $166,096.98. Following the sale, the chief executive officer now directly owns 877,608 shares in the company, valued at approximately $7,951,128.48. This represents a 2.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mineralys Therapeutics Stock Performance

NASDAQ MLYS traded up $0.71 on Wednesday, reaching $9.83. The company had a trading volume of 246,166 shares, compared to its average volume of 300,241. The company’s fifty day moving average is $12.37 and its 200-day moving average is $12.49. The firm has a market capitalization of $489.23 million, a price-to-earnings ratio of -3.01 and a beta of 1.49. Mineralys Therapeutics, Inc. has a 1-year low of $7.95 and a 1-year high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYSGet Free Report) last posted its quarterly earnings data on Monday, November 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period in the prior year, the business earned ($0.57) earnings per share. On average, research analysts forecast that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a report on Tuesday, November 12th.

Check Out Our Latest Report on Mineralys Therapeutics

Hedge Funds Weigh In On Mineralys Therapeutics

Hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its position in shares of Mineralys Therapeutics by 72.5% in the second quarter. Bank of New York Mellon Corp now owns 84,762 shares of the company’s stock worth $992,000 after purchasing an additional 35,634 shares in the last quarter. Rhumbline Advisers lifted its position in Mineralys Therapeutics by 82.1% during the 2nd quarter. Rhumbline Advisers now owns 41,079 shares of the company’s stock worth $481,000 after buying an additional 18,519 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Mineralys Therapeutics by 3.2% during the 2nd quarter. American Century Companies Inc. now owns 743,140 shares of the company’s stock worth $8,695,000 after buying an additional 23,170 shares during the last quarter. Federated Hermes Inc. grew its holdings in shares of Mineralys Therapeutics by 100.0% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $140,000 after acquiring an additional 6,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Mineralys Therapeutics by 95.0% in the 2nd quarter. Renaissance Technologies LLC now owns 61,800 shares of the company’s stock valued at $723,000 after acquiring an additional 30,100 shares in the last quarter. 84.46% of the stock is owned by institutional investors.

About Mineralys Therapeutics

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

Featured Articles

Insider Buying and Selling by Quarter for Mineralys Therapeutics (NASDAQ:MLYS)

Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.